Wang et al. reported that the expression of PANDAR (promoter of CDKN1A antisense DNA damage-activated RNA) is higher in cisplatin-resistant ovarian cancer tissues and cells from patients with wild-type p53 ovarian cancer than in cisplatin-sensitive cases [112]. Here, PANDAR is linked to ovarian carcinoma.